March 7th 2024
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Baricitinib for RA NDA Application Delayed at Least 18 Months
July 25th 2017Officials with the FDA are requesting a new clinical study before Eli Lilly and Incyte Corporation can resubmit for a new drug application (NDA) for baricitinib, a once-daily oral medication for moderate-to-severe rheumatoid arthritis treatment.
Read More